DETERMINATION AND EVALUATION OF LONG-TERM ABSORBED RADIATION DOSES OF RADIATION WORKERS WORKING IN TARGETED RADIONUCLIDE THERAPIES

Year 2023, Volume: 6 Issue: 1, 17 - 22, 28.02.2023

Nazenin İpek Işıkçı , Mustafa Demir, Ph.d.

https://doi.org/10.26650/JARHS2023-1170216

Abstract

Objective: It is aimed to determine the radiation doses to which radiation workers working in radionuclide treatments in nuclear medicine are exposed in the long term and to determine the contribution of each routine treatment procedure to these doses. Materials and Methods: The personal dosimetry records of doctors, nurses, health physicists, radiopharmacists, and cleaning staff, who routinely applied 131I treatment, 177Lu treatment, 90Y microsphere treatment, and 131I MIBG treatments were retrospectively analyzed for 6 years. The number of treatments performed in the same period and the persons assigned to these treatments were determined. Absorbed radiation doses of radiation workers in treatments and dose values per procedure were deduced from this information. Results: The highest average annual radiation dose was found to be 2185±1839 μSv in radiopharmacists. It was calculated as 786±943 μSv in nurses, 753±706 μSv in health physicists, 626±741 μSv in doctors and 961±1099 μSv in cleaning staff. The mean dose values calculated per procedure were found to be 129±208 μSv in the highest physicians. It was found 122±187 μSv in nurses, 76±122 μSv in health physicists, 76±52 μSv in radiopharmacists, and 42±64 μSv in cleaning staff. Conclusion: It was demonstrated that the annual radiation doses were within the permissible safe values and there was no excessive radiation exposure during radiopharmaceuticals preparation, administration to patients, and during the patients’ stay in the therapy unit.

Keywords

Absorbed dose, staff doses, radionuclide therapy, 131I therapy, 177Lu therapy

HEDEFLENMİŞ RADYONÜKLİT TEDAVİLERDE ÇALIŞAN RADYASYON GÖREVLİLERİNİN UZUN DÖNEM ABSORBE RADYASYON DOZLARININ BELİRLENMESİ VE DEĞERLENDİRİLMESİ

Abstract

Amaç: Nükleer tıpta radyonüklit tedavilerde çalışan radyasyon görevlilerinin uzun dönemde maruz kaldığı radyasyon dozlarının belirlenmesi ve rutin olarak yapılan her bir tedavi prosedürünün bu dozlara katkısının belirlenmesi amaçlanmıştır. Gereç ve Yöntem: 6 yıl boyunca rutin olarak İyot-131 (131I) tedavisi, (Lutesyum-177 (177Lu) tedavisi, Yittrium-90 (90Y) mikrosfer tedavisi ve 131I MIBG (Meta-İyodobenzilguanidin) tedavisi uygulayan doktor, hemşire, sağlık fizikçisi, radyofarmasist ve temizlik personelinin kişisel dozimetri kayıtları geriye dönük olarak incelendi. Aynı dönemde gerçekleştirilmiş olan tedavi sayıları ve bu tedavilerde görevli olanlar belirlendi. Bu bilgilerden radyasyon görevlilerinin tedavilerdeki absorbe radyasyon dozları ile prosedür başına doz değerleri çıkarıldı. Bulgular: Yıllık ortalama radyasyon dozları en yüksek radyofarmasistlerde 2185±1839 μSv bulundu. Hemşirelerde 786±943 μSv, sağlık fizikçilerinde 753±706 μSv, doktorlarda 626±741 μSv ve temizlik görevlisi personellerde 961±1099 μSv olarak hesaplandı. Prosedür başına hesaplanan ortalama doz değerleri en yüksek doktorlarda 129±208 μSv olarak bulundu. Hemşirelerde 122±187 μSv, sağlık fizikçilerinde 76±122 μSv, radyofarmasistlerde 76±52 μSv, temizlik görevlisi personellerde 42±64 μSv bulundu. Sonuç: Radyofarmasötiklerin hazırlanması sırasında, hastaya uygulanması sırasında ve hastanın tedavi servisinde yattığı süre boyunca doz aşımı olmamış, belirlenen radyasyon dozlarının izin verilen güvenli değerlerde olduğu tespit edilmiştir.

Keywords

Absorbe doz, personel dozları, radyonüklit tedavi, 131I tedavisi, 177Lu tedavi

References

• 1. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. physical and biological basis.Nucl Med Rev Cent East Eur 2012;15(2):120-3. google scholar
• 2. Devcic Z, Rosenberg J, Braat AJ, Techasith T, Banerjee A, Sze DY et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014;55(9):1404-10. google scholar
• 3. Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, BaumgaertnerI et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6(1):51-9. google scholar
• 4. Zang J, Fan X, Wang H, Liu Q, Wang J, Li H. et al. First-in-human study of 177LuEB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018;46(1):148-58. google scholar
• 5. Bayram T, Yilmaz AH, Demir M, Sonmez B. Radiation dose to technologists per nuclear medicine examination and estimation of annual dose. J Nucl Med Technol 2011;39(1):55-9. google scholar
• 6. IAEA Safety Series No. 63-Release of patients after radionuclide therapy; 2015. Available from: https://www-pub.iaea.org/MTCD/ Publications/PDF/pub1417_web.pdf google scholar
• 7. ICRP, 2007. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann. ICRP 37 (2-4). google scholar
• 8. IAEA Training Material on Radiation Protection in Nuclear Medicine. Dec, Part 5, Version; 2004. google scholar
• 9. Misdaq MA, Harrass H, Saikouk H, Matrane A. Dose to medical personnel. Health Phys 2020;118(2):129-35. google scholar
• 10. Lemoine J, Bourre JC, Giraud JY. Dosimétrie environnementale des patients à la suite de leur examen d’imagerie médicale. Radioprotect 2011;46(4):533-45. google scholar
• 11. Al-Mohammed HI, Sulieman A, Mayhoub FH, Salah H, Lagarde C, Alkhorayef M, Aldhebaib A. et al. Occupational exposure and radiobiological risk from thyroid radioiodine therapy in Saudi Arabia. Nature Portfolio 2021;11(1):145-57. google scholar
• 12. Bilska HP, Birkenfeld B, Gwarys A, Supinska A, Listewnik MH, Elbl B, et al. Occupational exposure at the Department of Nuclear Medicine as a work environment: A 19-year follow-up. Pol J Radiol 2011;76(2):18-21. google scholar
• 13. Willegaignon J, Paola Crema K, Oliveira NC. Pediatric 131I-MIBG Therapy for Neuroblastoma Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers,Medical Staff, and Radiation Safety Measures. Clin Nucl Med 2018;43(8):572-8. google scholar
• 14. Arora G, Mishra R, Kumar P, Yadav M, Ballal S, Bal C, Damle NA. Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of 177Lutetium-labeled Radiopharmaceuticals. Indian J Nucl Med 2017;32(2):89-92. google scholar
• 15. Lancelot S, Guillet B, Sigrist S, Bourrelly M, Waultier S, Mundler O and Pisanoa P. Exposure of medical personnel to radiation during radionuclide therapy practices. Nucl Med Commun 2008;29(4):405-10. google scholar
• 16. Harding LK. Radiation safety in the nuclear medicine department: impact of the UK Ionising Radiations Regulations. Br J Radiol 1987;60(717):915-18. google scholar
• 17. Ho WO, Wong KK, Leung YL, Cheng KC, Ho FTH. Radiation Doses to Staff in a Nuclear Medicine Department. J HK Coll Radiol 2002;5:24-8. google scholar
• 18. Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors,n Ann Nucl Med 2014;28(6):531-9. google scholar
• 19. Pant GS, Sharma SK, and Rath GK. Finger doses for staff handling radiopharmaceuticals in nuclear medicine. J Nucl Med Technol 2006;34(3):169-73. google scholar